$APTO
Aptose Biosciences Inc. Stock $apto

$apto Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000117184321007858 Filed on November 12, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.106M	$3.606M	$5.740M
YoY Change	-28.72%	-37.18%	155.11%
% of Gross Profit
Research & Development	$20.20M	$7.718M	$7.519M
YoY Change	125.18%	2.65%	58.26%
% of Gross Profit
Depreciation & Amortization	$44.00K	$36.00K	$37.00K
YoY Change	46.67%	-2.7%	12.12%
% of Gross Profit
Operating Expenses	$24.35M	$11.36M	$13.29M
YoY Change	64.96%	-14.56%	89.18%
Operating Profit
YoY Change
Interest Expense	$24.00K	$26.00K	$50.00K
YoY Change	-52.0%	-48.0%	-72.22%
% of Operating Profit
Other Income/Expense, Net		$26.00K	$45.00K
YoY Change		-42.22%	-75.41%
Pretax Income	-$24.32M	-$11.33M	-$13.25M
YoY Change	65.36%	-14.47%	93.71%
Income Tax
% Of Pretax Income
Net Earnings	-$24.32M	-$11.33M	-$13.25M
YoY Change	65.32%	-14.46%	93.59%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.27	-$0.13
Diluted Earnings Per Share	-$271.6K	-$127.4K	-$154.3K
COMMON SHARES
Basic Shares Outstanding	88.95M	88.95M	87.48M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$79.13M	$95.10M	$132.7M
YoY Change	-35.35%	-28.33%	339.4%
Cash & Equivalents	$39.11M	$75.10M	$99.73M
Short-Term Investments	$40.01M	$20.01M	$33.00M
Other Short-Term Assets	$133.0K	$131.0K	$115.0K
YoY Change	3.1%	13.91%	5.5%
Inventory
Prepaid Expenses	$2.476M	$1.034M	$1.106M
Receivables
Other Receivables
Total Short-Term Assets	$81.74M	$96.27M	$133.9M
YoY Change	-34.65%	-28.13%	337.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$323.0K	$353.0K	$272.0K
YoY Change	23.75%	29.78%	-24.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$788.0K	$932.0K	$1.313M
YoY Change	-33.56%	-29.02%	-29.1%
TOTAL ASSETS
Total Short-Term Assets	$81.74M	$96.27M	$133.9M
Total Long-Term Assets	$788.0K	$932.0K	$1.313M
Total Assets	$82.53M	$97.20M	$135.3M
YoY Change	-34.64%	-28.14%	316.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.699M	$1.630M	$1.529M
YoY Change	-21.74%	6.61%	30.24%
Accrued Expenses	$6.016M	$6.188M	$3.378M
YoY Change	46.66%	83.19%	52.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.174M	$8.300M	$5.444M
YoY Change	19.99%	52.46%	39.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$115.0K	$218.0K	$700.0K
YoY Change	-77.0%	-68.86%
Total Long-Term Liabilities	$115.0K	$218.0K	$700.0K
YoY Change	-77.0%	-68.86%	-36.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.174M	$8.300M	$5.444M
Total Long-Term Liabilities	$115.0K	$218.0K	$700.0K
Total Liabilities	$8.289M	$8.518M	$6.102M
YoY Change	12.82%	39.59%	21.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$422.5M	-$398.2M	-$342.4M
YoY Change	18.3%	16.28%	16.39%
Common Stock	$437.4M	$429.8M	$429.5M
YoY Change	1.83%	0.08%	47.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.24M	$88.68M	$129.2M
YoY Change
Total Liabilities & Shareholders Equity	$82.53M	$97.20M	$135.3M
YoY Change	-34.64%	-28.14%	316.69%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$24.32M	-$11.33M	-$13.25M
YoY Change	65.32%	-14.46%	93.59%
Depreciation, Depletion And Amortization	$44.00K	$36.00K	$37.00K
YoY Change	46.67%	-2.7%	12.12%
Cash From Operating Activities	-$16.04M	-$8.059M	-$8.270M
YoY Change	55.01%	-2.55%	59.53%
INVESTING ACTIVITIES
Capital Expenditures	-$14.00K	$181.0K	$0.00
YoY Change	-53.33%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$20.00M	-$4.000K	-$4.380M
YoY Change	-171.44%	-99.91%	338.0%
Cash From Investing Activities	-$20.01M	-$185.0K	-$4.398M
YoY Change	-171.57%	-95.79%	322.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$58.23M
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	66.00K	$0.00	$58.28M
YoY Change	65.0%	-100.0%	342741.18%
NET CHANGE
Cash From Operating Activities	-16.04M	-$8.059M	-$8.270M
Cash From Investing Activities	-20.01M	-$185.0K	-$4.398M
Cash From Financing Activities	66.00K	$0.00	$58.28M
Net Change In Cash	-35.99M	-$8.248M	$45.62M
YoY Change	-303.9%	-118.08%	-834.3%
FREE CASH FLOW
Cash From Operating Activities	-$16.04M	-$8.059M	-$8.270M
Capital Expenditures	-$14.00K	$181.0K	$0.00
Free Cash Flow	-$16.03M	-$8.240M	-$8.270M
YoY Change	55.33%	-0.36%	58.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4102000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	482000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	539000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8300000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6812000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	218000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	535000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	8518000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	7347000	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	429795000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	429523000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61384000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50861000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4316000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4316000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-398183000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357153000	USD
CY2021Q3	apto	Employee Stock Purchase Plan Maximum Payroll Deduction Percent EmployeeStockPurchasePlanMaximumPayrollDeductionPercent	0.15	pure
CY2021Q3	apto	Employee Stock Purchase Plan Stock Purchase Price Percent EmployeeStockPurchasePlanStockPurchasePricePercent	0.85	pure
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75095000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117393000	USD
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	88948744
CY2021Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2020Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2020	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88948744
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88948744
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88881737
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88881737
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	20006000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	5000000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1034000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2554000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	131000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	129000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	96266000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	125076000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	261000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	579000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	925000	USD
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	932000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1186000	USD
CY2021Q3	us-gaap	Assets Assets	97198000	USD
CY2020Q4	us-gaap	Assets Assets	126262000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1630000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2171000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6188000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0052	pure
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-3000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	69000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	484000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11333000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-13249000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40525000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	88680000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	118915000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97198000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	126262000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7718000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7519000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25777000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20319000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3641000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5775000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15322000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20690000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	11359000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	13294000	USD
	us-gaap	Operating Expenses OperatingExpenses	41099000	USD
	us-gaap	Operating Expenses OperatingExpenses	41009000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	46000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	72000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	485000	USD
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	4000	USD
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-17000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11333000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13251000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41030000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40542000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	88949000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85860000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	88927000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	79477000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	118915000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	160000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10635000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	93926000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	58234000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	531000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17007000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	88680000	USD
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	35000	USD
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	54000	USD
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4000	USD
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9000	USD
CY2021Q3	apto	Interest Accrued On Investments InterestAccruedOnInvestments	3000	USD
CY2020Q3	apto	Interest Accrued On Investments InterestAccruedOnInvestments	-9000	USD
	apto	Interest Accrued On Investments InterestAccruedOnInvestments	5000	USD
	apto	Interest Accrued On Investments InterestAccruedOnInvestments	-22000	USD
CY2021Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-788000	USD
CY2020Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	83000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1520000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	81000	USD
CY2021Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10000	USD
CY2020Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40525000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	129156000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11333000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-13249000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40525000	USD
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1828000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	4905000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10635000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17007000	USD
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	106000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	115000	USD
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	119000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	116000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	353000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	345000	USD
CY2021Q3	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	10000	USD
CY2020Q3	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	17000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26000	USD
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	139000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	136000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	416000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	401000	USD
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1284000	USD
CY2020Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-374000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-541000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-431000	USD
CY2021Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1905000	USD
CY2020Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	486000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2086000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	320000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8059000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8270000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27260000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23540000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	58234000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	58234000	USD
CY2021Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	49000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	160000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	531000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58283000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	160000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	58765000	USD
CY2021Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	4000	USD
CY2020Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	4398000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	15000000	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	15278000	USD
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	181000	USD
CY2020Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	198000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53000	USD
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-185000	USD
CY2020Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4398000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15198000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15331000	USD
CY2021Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4000	USD
CY2020Q3	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-9000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8248000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	45615000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42298000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19885000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	83343000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54112000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	117393000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79842000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75095000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99727000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75095000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	99727000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6188000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4102000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
	us-gaap	Use Of Estimates UseOfEstimates	<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:36pt;"/><td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant accounting policies, estimates and judgments:</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>there have been <em style="font: inherit;">no</em> changes to our significant accounting policies as described in our Annual Report on Form <em style="font: inherit;">10</em>-K for the fiscal year ended <em style="font: inherit;"> December 31, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The preparation of the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The impacts of such estimates are pervasive throughout the condensed consolidated interim financial statements and <em style="font: inherit;"> may </em>require accounting adjustments based on future occurrences.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:36pt;"/><td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(e)</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Concentration of risk:</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of <em style="font: inherit;">R1‑low</em> or A‑low investments and the Company invests only in highly rated corporations and treasury bills, which are capable of prompt liquidation.</p>
CY2021Q3	us-gaap	Cash Cash	180000	USD
CY2020Q4	us-gaap	Cash Cash	329000	USD
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	74915000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	117064000.000	USD
CY2020Q4	apto	Amortization Of Rightof Use Assets AmortizationOfRightofUseAssets	923000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	579000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	925000	USD
CY2019Q4	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1837000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11000	USD
CY2021Q3	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1855000	USD
CY2020Q4	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1848000	USD
CY2021Q3	apto	Amortization Of Rightof Use Assets AmortizationOfRightofUseAssets	1276000	USD
CY2021Q3	apto	Prepaid Research And Development PrepaidResearchAndDevelopment	843000	USD
CY2020Q4	apto	Prepaid Research And Development PrepaidResearchAndDevelopment	622000	USD
CY2021Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	191000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1932000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1034000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2554000	USD
CY2020Q4	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1848000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1917000	USD
CY2021Q3	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	3783000	USD
CY2020Q4	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	1932000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	20006000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	0	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20006000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5000000	USD
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	94921000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	122064000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1741000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	664000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	253000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11333000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	399000	USD
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	139000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	139000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	467000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	120000	USD
CY2021Q3	apto	Lessee Operating Lease Liability To Be Paid After Year Two LesseeOperatingLeaseLiabilityToBePaidAfterYearTwo	0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	726000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0539	pure
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0540	pure
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	482000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	539000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	218000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	535000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	700000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1074000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	129000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	132000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	388000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	136000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	416000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	401000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-13249000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40525000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12007000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.93
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4310000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.99
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10853000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.82
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7920000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M2D
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	88949000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85860000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	88927000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	79477000
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2021Q3	apto	Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares	6343242
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11942000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.97
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4199000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.04
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	67000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1205000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.47
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14869000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8092000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.55
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13851000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.67
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5941000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6352000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.82
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	215000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.49
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	71000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.87
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0127	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.818	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.859	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4199000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6352000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1828000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4905000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10635000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17007000	USD

Files In Submission

Name	View Source	Status
0001171843-21-007858-index-headers.html	Edgar Link	pending
0001171843-21-007858-index.html	Edgar Link	pending
0001171843-21-007858.txt	Edgar Link	pending
0001171843-21-007858-xbrl.zip	Edgar Link	pending
apto-20210930.xsd	Edgar Link	pending
apto-20210930_cal.xml	Edgar Link	unprocessable
apto-20210930_def.xml	Edgar Link	unprocessable
apto-20210930_lab.xml	Edgar Link	unprocessable
apto-20210930_pre.xml	Edgar Link	unprocessable
apto20210930_10q.htm	Edgar Link	pending
apto20210930_10qimg001.gif	Edgar Link	pending
apto20210930_10q_htm.xml	Edgar Link	completed
ex_304443.htm	Edgar Link	pending
ex_304444.htm	Edgar Link	pending
ex_304445.htm	Edgar Link	pending
ex_304446.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APTO
Aptose Biosciences Inc. Stock $apto

2021 Q4 Form 10-Q Financial Statement

#000117184321007858 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO Aptose Biosciences Inc. Stock $apto

2021 Q4 Form 10-Q Financial Statement

#000117184321007858 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO
Aptose Biosciences Inc. Stock $apto